Compare Bristol-Myers Squibb Co (BMY) vs iShares Self-Driving EV and Tech (IDRV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs iShares Self-Driving EV and Tech — how do they compare? Bristol-Myers Squibb Co trades at $58.05 (market cap $116.30B), while iShares Self-Driving EV and Tech trades at $36.65. The key difference: Bristol-Myers Squibb Co pays a 4.42% dividend while iShares Self-Driving EV and Tech pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, iShares Self-Driving EV and Tech nearer its low. Which is the better fit depends on your goals.
| BMY | IDRV | |
|---|---|---|
Market Cap | $116.30B | — |
Sector | Health | Sector/Thematic |
52-Week High | $62.37 | $45.48 |
52-Week Low | $42.60 | $32.13 |
Enterprise Value | $152.24B | — |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
IDRV trades at $36.35, down 1.38% with a bearish technical signal from moving averages. The ETF shows neutral oscillators but lacks disclosed fundamental ratios. Recent news highlights strong global EV sales growth, particularly in China and Europe, driven by high fuel prices and policy support, though U.S. adoption lags.
Outlook is mixed: positive EV industry momentum contrasts with technical weakness and U.S. market challenges. Key risks include regulatory shifts, competition, and reliance on macroeconomic factors. Investors should weigh sector growth against ETF-specific performance and market sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About iShares Self-Driving EV and Tech
IDRV invests in global companies at the forefront of self-driving and electric vehicle innovation. It provides exposure to the full EV value chain, including battery technology and autonomous systems, with top holdings like Albemarle, Rivian, and Tesla.
Read more on IDRV →
